June 17, 2004
New therapeutic option for the treatment of erectile dysfunction

Levitra® available in Japanese pharmacies from Monday

Levitra® is the first new alternative treatment in five years

Leverkusen / June 17, 2004
- Bayer Yakuhin, Ltd., Osaka, the Japanese
subsidiary of Bayer HealthCare, Leverkusen, will launch Levitra® in Japan on
Monday, June 21, 2004. Levitra® will then be available in 76 countries around
the world. The Japanese Ministry for Health, Labor and Welfare granted Levitra®
marketing authorization in April.

It is estimated that approximately 11 million men in Japan suffer from erectile
dysfunction. However, only about 10 % of these men currently seek medical
advice or help from their physician to treat their condition.

Levitra® is a prescription-only drug product in Japan.

Bayer HealthCare AG, a subgroup of Bayer AG with sales of approximately 8.9
billion Euro in 2003, is one of the world's leading, innovative companies in
the health care and medical products industry.

The company combines the global activities of the divisions Animal Health,
Biological Products, Consumer Care, Diagnostics Professional Testing Systems
and Diagnostics Self Testing Systems and Pharmaceuticals. 34,600 people are
employed by Bayer HealthCare worldwide.

Our aim is to discover and manufacture innovative products that will improve
human and animal health worldwide. Our products enhance well-being and quality
of life by diagnosing, preventing and treating disease.

Forward-looking statements<br/>
This news release contains forward-looking statements based on current
assumptions and forecasts made by Bayer Group management. Various known and
unknown risks, uncertainties and other factors could lead to material
differences between the actual future results, financial situation, development
or performance of the company and the estimates given here. These factors
include those discussed in our public reports filed with the Frankfurt Stock
Exchange and with the U.S. Securities and Exchange Commission (including our
Form 20-F). The company assumes no liability whatsoever to update these
forward-looking statements or to conform them to future events or developments.